hotspot -WSS

hotspot

author：comprehensive 2025-09-29 23:04:52 - browse：8

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

hotspot

WSS

UCB departs biotech trade group BIO

Pfizer plans to depart BIO

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Why psychiatrists like me stop taking insurance

FDA needs staff influx to meet gene therapy needs, Marks says

GSK Flovent asthma inhalers replaced by authorized generics

explore

hotspot

The next ALS data readout — overdue but important

explore

The high cost of giving birth even with insurance

Burning questions for the 2024 JPM Healthcare Conference

Jerome Adams on the need for new antivirals for Covid

Congenital heart disease patients face new threat of heart failure

DIEP, the 'gold standard' of breast reconstruction, is under threat

Patients' immediate access to test results puts radiologists in a bind

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Pharma patents targeted by Biden in move to slash drug prices

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

AI models in health care face new federal disclosure requirements

focus

New weight loss drugs work. But how can they best be used?

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Teach medical students about patients with intellectual disabilities

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Videos point to link between seizures and unexplained toddler deaths

What causes an itch? Researchers may have solved the mystery

hotspot

leisure time

leisure time

hotspot